Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2019

Evidence for altered neurodevelopment and neurodegeneration in
Wolfram syndrome using longitudinal morphometry
Heather M. Lugar
Washington University School of Medicine in St. Louis

Jonathan M. Koller
Washington University School of Medicine in St. Louis

Jerrel Rutlin
Washington University School of Medicine in St. Louis

Sarah A. Eisenstein
Washington University School of Medicine in St. Louis

Olga Neyman
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Lugar, Heather M.; Koller, Jonathan M.; Rutlin, Jerrel; Eisenstein, Sarah A.; Neyman, Olga; Narayanan,
Anagha; Chen, Ling; Shimony, Joshua S.; and Hershey, Tamara, ,"Evidence for altered neurodevelopment
and neurodegeneration in Wolfram syndrome using longitudinal morphometry." Scientific Reports. 9,.
6010. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/7686

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Heather M. Lugar, Jonathan M. Koller, Jerrel Rutlin, Sarah A. Eisenstein, Olga Neyman, Anagha Narayanan,
Ling Chen, Joshua S. Shimony, and Tamara Hershey

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/7686

www.nature.com/scientificreports

OPEN

Received: 1 October 2018
Accepted: 1 April 2019
Published: xx xx xxxx

Evidence for altered
neurodevelopment and
neurodegeneration in Wolfram
syndrome using longitudinal
morphometry
Heather M. Lugar1, Jonathan M. Koller 1, Jerrel Rutlin1, Sarah A. Eisenstein1, Olga Neyman1,
Anagha Narayanan1, Ling Chen3, Joshua S. Shimony2 & Tamara Hershey 1,2
Wolfram syndrome is a rare disease caused by mutations in the WFS1 gene leading to symptoms in
early to mid-childhood. Brain structural abnormalities are present even in young children, but it is not
known when these abnormalities arise. Such information is critical in determining optimal outcome
measures for clinical trials and in understanding the aberrant neurobiological processes in Wolfram
syndrome. Using voxel-wise and regional longitudinal analyses, we compared brain volumes in Wolfram
patients (n = 29; ages 5–25 at baseline; mean follow-up = 3.6 years), to age and sex-equivalent controls
(n = 52; ages 6–26 at baseline; mean follow-up = 2.0 years). Between groups, white and gray matter
volumes were affected differentially during development. Controls had uniformly increasing volume
in white matter, whereas the Wolfram group had stable (optic radiations) or decreasing (brainstem,
ventral pons) white matter volumes. In gray matter, controls had stable (thalamus, cerebellar cortex)
or decreasing volumes (cortex), whereas the Wolfram group had decreased volume in thalamus and
cerebellar cortex. These patterns suggest that there may be early, stalled white matter development
in Wolfram syndrome, with additional degenerative processes in both white and gray matter. Ideally,
animal models could be used to identify the underlying mechanisms and develop specific interventions.
Wolfram syndrome (OMIM #222300) is a rare (1 in 500,000 to 1,000,000) autosomal recessive genetic disease
originally described as the combination of insulin dependent diabetes mellitus, optic nerve atrophy, diabetes
insipidus and deafness1. Neurodegeneration and neurological features were thought to appear at later stages of the
disease, ultimately leading to death in middle adulthood2. Since the major causative gene (WFS1)3 was identified
in 1998, greater variability in the severity of the disease, the complexity of the phenotype and the rate of progression has been revealed. It is now evident that not all of the presumed core symptoms of Wolfram syndrome are
present in all of the patients who are genetically identified4–6 and that neurologic abnormality is present even
at early stages of the disease in some patients7–9. Rare neuropathological examinations of Wolfram syndrome
patients’ brains have noted loss of neurons, myelin and myelinated axons10–14; however it is unclear when in the
disease process these occur. Given that the neurological features of Wolfram syndrome are life-threatening and
evolve over development, these aspects should be targets of intervention and thus require greater attention.
Mutations in the WFS1 gene predispose pancreatic β-cells to ER stress-mediated apoptosis15–22 and this mechanism may also account for central nervous system degeneration, including, perhaps, myelin degradation23.
However, this idea has not been well tested in brain cells, nor do we understand how this mechanism interacts
with neurodevelopmental processes. While molecular and cellular experiments have led the field closer to identifying potential interventions for degenerative processes in Wolfram syndrome, the identification of reliable
neurological biomarkers and an understanding of underlying neuropathophysiology and clinical correlates is in
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its infancy. For these reasons, determining the trajectory of structural brain changes in Wolfram syndrome during
development is a critical step forward for the field.
In our previous cross-sectional neuroimaging study, individuals with Wolfram syndrome, as compared to age
and sex equivalent controls, had reduced gray and white matter volumes primarily in the ventral pons, brainstem,
cerebellum, and thalamus with altered white matter microstructural integrity in tracts such as optic radiations9,24.
Interestingly, decreased brainstem and cerebellar volumes were seen in almost all individuals with Wolfram
syndrome, regardless of age or duration of diabetes or other features of the disease. These data suggested that
Wolfram syndrome affects the early development of specific brain regions. However, cross-sectional comparisons
cannot determine whether these abnormalities evolve over time within an individual or at what rate, nor how
they are distinguished from normal developmental trajectories. Thus, we have performed yearly neuroimaging
studies in patients with Wolfram syndrome and controls over an age range of active neurodevelopment. By examining morphometric change with multiple spatial and statistical methods, we aim to converge on the regions
and tissue types that are most affected in Wolfram syndrome, distinguish between earlier vs. later occurring
abnormalities and identify rates of regional change that diverge from normal neurodevelopmental trajectories.
Findings may indicate future targets for brain-specific intervention and identify outcome measures for clinical
trials targeting neurological symptoms. It will also greatly expand our understanding of the longitudinal phenotype of WFS1-related disorders, rather than classically defined Wolfram syndrome. Such knowledge will have a
significant impact on patients and families by allowing physicians to provide more accurate prognoses.

Methods

Participants. This study was approved by the Human Research Protection Office at Washington University in
St. Louis and all methods were conducted in accordance with relevant guidelines and regulations. Children under
age 18 gave informed assent and parents/guardians gave informed, written consent. Participants 18 or older gave
informed, written consent.
Wolfram syndrome group. Patients were recruited into the Washington University Wolfram Syndrome Research
Clinic through self or physician referral or from the Washington University Wolfram Syndrome Registry. Patients
had to have known WFS1 mutations, be under the age of 30 at enrollment and aware of their diagnosis, and be
able to travel to St. Louis for annual research clinic visits. Patients were evaluated annually by physician specialists, answered questionnaires and performed different tests. Data from some of these measures have been
previously reported5,7–9,25–34. Each patient was also assessed by a neurologist who performed the Wolfram Unified
Rating Scale (WURS), a scale designed to measure the severity of symptoms commonly associated with Wolfram
syndrome26. We used the physical subscale as a measure of neurologic symptom severity. Wolfram patients without contraindications also underwent magnetic resonance imaging (MRI) at each visit.
Control group. Healthy individuals with and without type 1 diabetes mellitus composed the control group.
Participants with type 1 diabetes were recruited from the Pediatric Diabetes Clinic at St. Louis Children’s Hospital
and Washington University School of Medicine in St. Louis. They were excluded for diagnosed psychiatric disorder, significant neurological history not due to diabetes, known premature birth (<36 weeks gestation) with complications, psychoactive medications, or physical limitations that would interfere with testing. No participants
had known retinopathy, nephropathy or neuropathy at the time of testing. Non-diabetic individuals were either
healthy siblings of the participants with diabetes or from the community. Non-diabetic controls were excluded
for known current or past history of neurological and psychiatric diagnoses or other significant health conditions.
Each participant in these control groups underwent MRI scans, answered questionnaires and completed cognitive tests at each annual visit for up to 3 years.

Neuroimaging. Before beginning scanning, participants with diabetes were determined to always have blood

glucose levels above 70 mg/dl, and below 300 mg/dl when possible. Scanning was performed on a single Siemens
3T Tesla Tim Trio at Washington University and included T1 and T2-weighted sequences. The T1-weighted
Magnetization-Prepared Rapid Gradient-Echo (MPRAGE) sequence had the following parameters: sagittal
acquisition, repetition time (TR) = 2400 ms, echo time (TE) = 3.16 ms, inversion time (TI) = 1000 ms, voxel resolution = 1 × 1 × 1 mm, time = 8:09 min. The T2-weighted sequence had the following parameters: sagittal acquisition, TR = 3200 ms, TE = 455 ms, voxel resolution = 1 × 1 × 1 mm, time = 4:43 min. All imaging sessions with
acceptable T1 and T2 scans were selected for analyses. Diffusion-weighted, limited field of view T2, and resting
BOLD scans were also attempted, but data are not reported here.
Analysis methods were selected to provide complementary and convergent information on how gray and
white matter volumes change over time in Wolfram syndrome and controls. We used a voxel-wise imaging analysis approach that disregarded anatomical boundaries and tissue types and a region of interest (ROI) method,
independently analyzed with appropriate statistical models for varying numbers of time points across participants. Since previous analyses have not found differences between healthy and diabetic groups9,24, we pooled the
control groups and included the presence of diabetes as a covariate in the model to simplify statistical analyses
and to maximize power.
Voxel-wise analysis methods. For each participant with two or more time points, a T1 and a T2 from each time
point was processed using the serial longitudinal registration toolbox in SPM 12 with default settings35. For each
time point per participant, the T2 was co-registered to the corresponding T1 from that visit. The deformation
maps from the T1 longitudinal registration were then used to sample the T1 and T2 for each time point onto
the mid-point average T1 longitudinal registration space and make an all-time-point average for both the T1
and T2. The all-time-point average T1 and T2 were used as inputs for SPM segment36. Using both the T1 and
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T2 images in SPM segment can improve segmentation accuracy (https://www.fil.ion.ucl.ac.uk/spm/doc/manual.
pdf). The resulting gray and white matter tissue probability maps (TPMs) for each participant were used to create
study-specific gray and white matter templates using SPM’s DARTEL37. These templates were used to align each
subject’s gray and white matter TPMs to a common group template space. To achieve a better correspondence
with the MNI152 VI asymmetric template (MNI152_VIa) (http://nist.mni.mcgill.ca/?page_id=714), we segmented the MNI152_VIa T1 template image with SPM segment and used SPM DARTEL to compute a mapping
between MNI152_VIa and the common group template created from our data. For each person, we then took
their average gray and white matter TPMs and the Jacobian determinant maps for each time point and warped
them into MNI152_VIa space using the composite warp from subject space to MNI152_Via space. Each Jacobian
determinant map (tensor-based morphometry map, “TBM”) represents degree of expansion or contraction from
a template (subject or group) at the voxel level. The group-average gray and white matter TPMs were used to
create a mask for voxel-wise analyses.
The sandwich estimator toolbox (SwE, version 1.2.8 for SPM) was used to statistically analyze TBM’s38.
The SwE toolbox optimizes the analysis of longitudinal neuroimaging data by accommodating datasets that
are small, unbalanced, and have missing data. SwE applies a non-iterative, marginal model to the data which
allows each group to have its own covariance matrix and prevents within-subject convergence problems inherent in longitudinal designs. The main effect of group (Wolfram vs controls) was tested by using the TBMs for
time-point-to-group-template, while controlling for estimate of total intracranial volume (eTIV39), age, sex, and
diabetes. Annualized change in volume (defined as time in years from each time point to the mid-point for each
TBM) was modelled as a fixed effect. The interactions of group by time by age and of group by time, as well as
the main effect of time within each group were tested using the TBMs for time-point-to-midpoint-average while
controlling for age, sex, and diabetes. The wild bootstrap (WB) component of the SwE toolbox was used to make
non-parametric inferences about cluster level data using family-wise error (FWE) correction (http://hdl.handle.
net/2268/186284). A cluster-forming threshold of p = 0.001 was used for the 999 bootstrap permutations, and
FWE-corrected cluster-level p values were considered significant at p < 0.05.
Regions of interest (ROI) methods. For all participants with a T1 from at least one time point, the semi-automatic
segmentation program Freesurfer (v5.3) was used to extract global and regional gray and white matter volumes
at each time point using the longitudinal processing stream24,40. Specific regional volumes were selected for analysis to match the location of major clusters on voxel-wise group by time interaction maps that survived FWE
correction. Regional volumes were averaged across left and right hemispheres when appropriate and corrected
for eTIV39. Volumes for ventral pons were measured by first aligning the Freesurfer brainstem ROIs for each
participant across all time points and then averaging them. Manual segmentation was then performed on each
individual’s average brainstem ROI using previously described methods24 before applying those segments back to
each time point, and extracting eTIV-corrected volumes9,24.
Statistical analyses assumed a linear relationship between regional brain volumes and time and used a random
slope model (mixed model) to predict average annual rate of change for each regional volume. This model allowed
slopes (annual rate of change) to vary randomly between participants and fit a separate regression line for each
participant. The three-way interaction between group, time and age at the first testing session and all the two-way
interactions, as well as sex and diabetes effect, were considered in a full model. Backward selection method was
used to remove the most non-significant factor, one at each step, in the order of three-way interaction, two-way
interactions and main effects. Analyses were two-tailed with a significance level of 0.05 and performed with SAS
9.4 (SAS Institute, Cary, NC).
Power analyses were performed on the region with the greatest degree of abnormal change within just the
Wolfram group to determine the sample size necessary to detect a significant effect of intervention in a clinical
trial. Simulations were conducted to determine the sample size required to achieve at least 80% power to detect
a 50% or 60% reduction in mean annual rate of progression at significance level of 0.05. Analyses assumed that
measurements would occur every six months during a 3-year clinical trial, and that sample sizes and mean volumes at baseline were equal for the two Wolfram groups (treatment vs. placebo). Mean trajectories were simulated using the random slope model, using a mean annual rate of progression for the placebo group estimated
from the current Wolfram data. Simulations assumed random slope and homoscedastic error normally distributed with zero mean and variance estimated from the Wolfram group data. Empirical power was calculated from
1000 simulated trials.

Results

Participants. Wolfram syndrome group. Adequate T1 and T2 images were acquired on 29 patients with
Wolfram syndrome seen annually between 1 and 7 times (mean follow-up = 3.64 years) (Table 1).
Control group. Adequate T1 and T2 images were acquired on 24 type 1 diabetics and 28 non-diabetic participants, annually between 1 and 3 times (mean follow-up = 2.0 years). The type 1 diabetes group had overall higher
HbA1c than the Wolfram group (sessions 1–3, p < 0.022), however, these groups did not differ in blood glucose
levels before or after scans (sessions 1–3, p > 0.23) or in diabetes duration (t(51) = −0.07, p = 0.95). Wolfram and
control groups did not differ in age at their first visit (baseline age range 5–25 and 6–26, respectively; t(79) = 0.09,
p = 0.93) or in sex distribution (χ2 (1, 81) = 0, p = 0.99). See Table 1 for demographics and Fig. 1 for a plot of all
participant ages and number of sessions.

Neuroimaging.

Voxel-wise results. To confirm our previous cross-sectional neuroimaging findings in
Wolfram syndrome, we first examined the main effect of group on cluster-wise bootstrap-corrected FWE P
images. We found that the Wolfram group had lower volumes in the brainstem, cerebellum and thalamus and
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Control Subsets
Wolfram
(n = 29)

Controls
(n = 52)

Non-diabetic
controls
(n = 28)

Diabetic
controls
(n = 24)

M/F

15/14

27/25

13/15

14/10

Mean ± SD

13.8 ± 5.5

13.9 ± 5.0

14.1 ± 5.3

13.6 ± 4.7

Range

5.9–25.8

6.0–26.2

6.0–26.1

7.6–26.2

Variable
Sex
Age (years)
*Follow-up period
(years)

Mean ± SD

3.6 ± 1.7

2.0 ± 0.3

1.9 ± 0.3

2.0 ± 0.2

Range

1.0–5.9

1.0–2.3

1.0–2.3

1.1–2.3

Diabetes duration
(years)

Mean ± SD

7.9 ± 5.2

—

—

7.8 ± 4.8

Range

0.4–16.6

—

—

0.1–16.7

Diabetes mellitus

Prevalence

29/29

—

—

—

Mean ± SD

5.9 ± 3.0

—

—

—

Range

2.7–13.9

—

—

—

Prevalence

18/29

—

—

—

Mean ± SD

11.0 ± 3.8

—

—

—

Range

5.5–17.0

—

—

—

Prevalence

20/29

—

—

—

Mean ± SD

10.5 ± 4.7

—

—

—

Range

6.0–25.8

—

—

—

Prevalence

28/29

—

—

—

Mean ± SD

10.1 ± 3.9

—

—

—

Range

3.8–18.0

—

—

—

Age at dx (years)
Diabetes insipidus
Age at dx (years)
Hearing loss
Age at dx (years)
Optic nerve atrophy
Age at dx (years)

Table 1. Mean and standard deviation (SD) of demographic and clinical variables across Wolfram and control
groups at session 1. There were no differences between the Wolfram and control groups for age (p = 0.93) or
sex (p = 0.99), and there were no differences between Wolfram and the diabetic control groups for duration of
diabetes (p = 0.95) at session 1. *Excludes participants with a single time point (Wolfram, n = 4; Non-diabetic
control = 6; diabetic control = 6). Abbreviations: M, male; F, female; dx, diagnosis.

Figure 1. Ages of the 81 participants at each of their MRI scans. Each row on the Y-axis indicates an individual
participant and symbols (connected by a line) indicate the participant’s age at each session (X-axis). Wolfram
participants are shown in red and controls are shown in blue.

slightly higher volumes in restricted temporal lobe cortex compared to controls (Fig. 2a). These findings largely
overlap with our previous cross-sectional results which used smaller sample sizes and different analytic methods9,24. The current analysis further revealed that the Wolfram group had lower volumes than controls in the
cerebellar and cerebral peduncles and internal capsule.
No clusters from the group by time by age interaction survived cluster-wise FWE correction. Significant group
by time interactions were found within the brainstem, notably in the ventral pons, posterior thalamus, internal
capsule, optic radiations, a small portion of the visual cortex, most of cerebellar white matter, a portion of cerebellar gray matter, cerebellar peduncles, and cerebral peduncles (Fig. 2b). In order to better understand the nature
of these interactions, we examined the voxel-wise main effect of time within each group separately. These maps
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Figure 2. Clusters surviving FWE correction in each voxel-wise analysis at FWE p < 0.05. (a) Main effect of group:
The Wolfram group has lower volume (yellow clusters) in multiple regions (e.g. brainstem, cerebellum, thalamus)
and greater volume (blue) in relatively small portions of cortex compared to the control group. (b) Group × time
interaction: Clusters where groups differed over time in volume (green) largely fell within the regions where the
Wolfram group had lower volume than controls (yellow in a). (c) Main effect of time within the control group:
Volume increased in most white matter regions (yellow and red clusters) and decreased in cortical gray matter
regions (turquoise and blue) over time, as expected. (d) Main effect of time within the Wolfram group: Volume
decreased over time (turquoise) in many white and gray matter regions, and no increased volume was seen
anywhere in the brain. Expansion = increase in volume over time; Contraction = decrease in volume over time.

Group × Time
Interaction

Main Effect of
Time: Wolfram

±SEM

F

p

F

17.71

70.03

<0.001

8.71

12.34

31.69

<0.001

2.62

0.117

248.91

18.02

32.52

<0.001

1.49

0.232

82.49

−49.26

60.43

6.83

0.01

13.42

0.001

5.86

11.26

4.81

34.60

<0.001

49.47

<0.001

Wolfram (n = 29)

Controls (n = 52)

Brain Region

Mean

±SEM

Mean

Brainstem

−123.61

26.08

182.39

−48.44

18.33

93.23

24.32

26.24

−420.95
−84.68

Ventral Pons
Cerebellar White
Cerebellar Gray
Thalamus

p
0.006

Table 2. Mixed model results for regions of interest. Mean and standard error of the mean (SEM) of the
estimated annual rates of change are shown for each region and group. F and p values for each region come from
the interaction of group by time, controlling for age, sex, and diabetes, and the main effect of time within the
Wolfram group, controlling for age and sex. Significant results at the p ≤ 0.01 level are in bold.
indicate that within controls, as expected based on the literature, volumes increased across most major white matter regions, including brainstem and cerebellar white matter, whereas cortical gray matter volume decreased over
time, particularly within the precuneus/cuneus and prefrontal cortex (Fig. 2c). In contrast, within the Wolfram
group, white matter volumes did not show any increase over time. In addition, the ventral pons region of the
brainstem and cerebellar white matter actually decreased in volume over time (Fig. 2d). Thalamus and cerebellar
gray matter volume decreased in Wolfram over time, but was stable in controls.
Regions of interest (ROI) results. Based on the voxel-wise group by time findings, we selected brainstem, ventral
pons, thalamus, cerebellar gray and cerebellar white matter regions. As expected, these regions all had significant
interactions between group and time (p < 0.01; Table 2) and none had any group by time by age interactions,
recapitulating the patterns observed in the voxel-wise analyses. In brainstem, ventral pons and cerebellar white
matter, controls tend to increase in volume over time and age and the Wolfram group tend to decrease in volume
over time and age (Fig. 3a–c). In the thalamus, we observed a striking decrease in volume in the Wolfram group
over time while controls remained stable (Fig. 3e). Cerebellar gray matter decreased in both groups, but was more
accentuated in the Wolfram group (Fig. 3d).
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Figure 3. Volumes of regions of interests (corrected for eTIV) over time and age. All regions had a significant
interaction of group by time. (a) Brainstem, (b) Ventral pons, (c) Cerebellar white matter, (d) Cerebellar
gray matter, and (e) Thalamus. Freesurfer-derived volume is on the Y-axis and age is on the X-axis. Markers
connected by a line denote age at each session for an individual over time. Open markers represent controls
while solid markers represent Wolfram participants.

Based on random slope models, the rate of change in each brain region was calculated for each person. As
expected based on the group by time interactions from the mixed models, the average rate of change was significantly different between the two groups for all regions (p < 0.001). In addition, within the control group,
average rate of change was different from 0 (p < 0.03) for each region except for cerebellar gray matter. Within
the Wolfram group, the average rate of change was different from 0 (p < 0.02) for all regions except for cerebellar
white matter (Fig. 4). To explore how degree of symptom severity at entry to the study predicted change over
time, we performed Spearman’s correlations between annual rate of change variables and the WURS Physical
Scale Score (n = 5 correlations). The correlation between thalamic rate of change and WURS Physical survived
Bonferroni correction (criterion p value 0.05/5 = 0.01; rs = −0.669, p = 0.003, n = 17; Fig. 5).
Within group mixed model analyses for the main effect of time within the Wolfram group determined that the
largest effect was in the thalamus (F1,28 = 49.47, p < 0.0001; Table 2). Power analyses on the estimated annual rate
of change in thalamus estimated that it would require 34 or 48 patients per study arm (treatment vs placebo) to
detect a 60% or 50% slowing of the rate of volume loss due to an intervention.

Discussion

Our longitudinal morphometric neuroimaging study of Wolfram syndrome identified the brain regions and tissue types that follow abnormal trajectories across development in this disease. Wolfram syndrome appears to be
associated with deficient and stalled white matter growth and abnormal loss of white and gray matter in specific
regions over time. The patterns observed suggest that there may be different mechanisms underlying the brain
abnormalities present early in disease (hypo- and stalled myelination) vs. the evolution of abnormalities across
Scientific Reports |

(2019) 9:6010 | https://doi.org/10.1038/s41598-019-42447-9

6

www.nature.com/scientificreports/

www.nature.com/scientificreports

Figure 4. Mean (±SEM) estimated annual percent rate of change for regions of interest. Each individual’s
estimated slopes from the mixed model analysis were scaled by their average volumes to calculate annual
percent change for each region. Mean annual percent change for each region across groups is shown with the
control group on the left and the Wolfram group on the right. Error bars represent standard error of the mean.
*p < 0.05, one tailed t-test vs. 0.

Figure 5. Correlation between percent change in thalamic volume and WURS physical score in Wolfram
participants. Greater physical symptom severity (higher WURS score) at enrollment was associated with greater
negative change in thalamic volume over time (rs = −0.669, p = 0.003, n = 17).

development (axonal and neuronal degeneration). In addition, abnormal trajectories were found preferentially
in the brainstem, cerebellum, thalamus and the white matter tracts that connect them while most of higher order
cortex followed normal developmental trends in Wolfram syndrome. Finally, our findings suggest that thalamic
volume is a novel and potentially useful biomarker for neurodegeneration in Wolfram syndrome, with the statistical power appropriate for small clinical trials. Together, these results suggest regionally specific neurodevelopmental and neurodegenerative processes at work that ultimately may explain the trajectory of neurological
symptoms and provide data highly relevant to ongoing and future clinical trials in Wolfram syndrome.
Normal neurodevelopment, as reflected by tissue volume, is dynamic and multifactorial. In general, from
childhood to early adulthood, white matter volume increases linearly, likely due to ongoing myelination of axons.
In contrast, cortical gray matter volume peaks at an early age and then decreases over development, likely due to
synapse elimination and dendritic pruning41–44. These processes also differ regionally, with higher order cortical
regions developing later than primary sensory areas43–46. For example, primary visual and motor cortex reaches
peak thickness around age 8, whereas prefrontal cortical gray matter reaches peak thickness around age 11, after
which they decline to adulthood in a fairly linear manner47. Volumes for subcortical regions peak at about 13–19
years of age48 but the rate of increases and decreases are much more muted than for cortical gray matter44,49.
Volumetric results from our control group recapitulated these known patterns in this age range, demonstrating
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mostly increasing volume in white matter, decreasing volume in cortical gray matter and relatively stable volume
in subcortical gray matter. The complexities of these normal trajectories are an important backdrop for understanding the specific impact of Wolfram syndrome on the brain.
Over time, brain volumes in Wolfram syndrome appear to deviate from normal trajectories in a region and
tissue-specific manner. Interestingly, we found no significant interactions with age, suggesting that group differences in trajectories are not dependent on the age of the individual. This result could mean that other factors
are more powerful in driving individual differences in neurodegenerative processes in Wolfram than just age
(e.g. severity of mutation) or that our sample is not large or diverse enough in age to be able to detect a 3-way
interaction.
In white matter regions that increase in volume across normal development, the Wolfram group had stable
(optic radiations, frontal white matter) or decreasing volume (cerebellar white matter, brainstem, pons). These
findings suggest that Wolfram syndrome may interfere with the ability to myelinate existing axons over age and,
in some regions, cause damage to myelin and/or axons. In addition, we observed lower white matter volumes
at very early ages (e.g. 5), which may suggest an early lack of myelin and/or axonal development. Our previous
cross-sectional diffusion tensor imaging (DTI) analyses were consistent with hypomyelination24, but longitudinal
DTI analysis could help determine the impact of Wolfram syndrome on myelin vs. axons over time. It is possible
that, as in other demyelinating diseases (e.g. multiple sclerosis50), lack of myelination precedes axonal damage,
axonal loss and finally neuronal loss28. Longitudinal DTI analyses that may allow for these more detailed neurobiological interpretations are underway but outside the scope of this paper.
In gray matter regions that decrease in volume over this age range (cortex, cerebellum), the Wolfram group
demonstrated a relatively normal trajectory of decreasing volume (cortex), except for a very small part of visual
cortex and cerebellar cortex, which appeared to have accelerated decreases in volume. In normal development,
decreased gray matter volume is thought to reflect synaptic and dendritic pruning51. Thus, it may be that Wolfram
syndrome is associated with accelerated or excessive pruning or cell death in these restricted areas. In gray matter
that is relatively stable over this age range (subcortex)46, the Wolfram group demonstrated an abnormal decrease
in thalamic volume, but no differences in the other regions. We hypothesize that this pattern is most consistent
with neuronal loss, perhaps due to loss or dysfunction of axons that project to or from thalamic nuclei as seen
in other neurodegenerative diseases52. Interestingly, the voxel-wise findings appeared predominantly within the
posterior thalami, which is composed of nuclei with inputs and outputs to the visual system, including pulvinar, lateral posterior and lateral geniculate nuclei53. Segmentation of thalamic nuclei might help us understand
structure-function relationships and improve its use as a biomarker of neurodegeneration54. Further, rate of
change in thalamic volume was predicted by disease severity (WURS Physical score) at time 1, suggesting that
thalamic neuronal loss may be a later appearing sign in Wolfram syndrome, and have some clinical relevance. We
determined that to detect a 50% slowing of thalamic volume loss, a clinical trial would require 34 patients per arm
(treatment vs placebo) to achieve power of >0.80, which would be feasible even for an ultra-rare disease such as
Wolfram syndrome.
Neuropathological studies of individuals with Wolfram syndrome are rare and findings have been somewhat
variable. However, if these cases are arranged according to the age and severity of the patient, there does appear to
be some support for an evolution of neuropathological findings from restricted myelin and axonal loss to widespread myelin, axonal and neuronal loss. Neuropathological examination of a 15 year old who died accidentally
revealed reduced myelin and axons in restricted areas and neuronal loss only in the hypothalamus11. Exam results
from a 21 year old with more extensive symptoms were similar but also included myelin and axon loss in the optic
radiations and diffuse demyelination throughout the rest of the brain11. A 24 year old with advanced neurological
symptoms at the time of death had widespread axonal loss and neuronal death10. Similarly, a 36 year old with
severe neurologic symptoms at time of death had severe loss of myelin and presence of gliosis in the optic nerves
and loss of myelin and neurons in the cerebellum55. Finally, a 38 year old patient with advanced symptoms at the
time of death had axonal swelling and dystrophy, neuronal loss and gliosis in brainstem, cerebellum and optic
nerves, and also neuronal loss and gliosis in thalamus56. Of note, these cases were all published before the age
of genetic confirmation for Wolfram syndrome, used different methods and in some cases did not examine the
entire brain, and so need to be viewed with some caution. Despite these caveats, it appears that cases with greater
symptom severity may have more widespread axonal and neuronal pathology.
The functional consequences of these neurodevelopmental and neurodegenerative changes in Wolfram syndrome are unclear. However, we can speculate that white matter loss in the brainstem and pons could affect a
wide range of motor, sensory and other essential functions (e.g. respiration, urination) known to be affected
in Wolfram syndrome. In fact, in a cross-sectional, correlational analysis, we found that ventral pons volume
correlated with the degree of urinary dysfunction30. In addition, gait and balance, which are associated with the
cerebellum, are known to be abnormal in Wolfram syndrome, even at the early stages of the disease process7,8.
Ultimately, we hope to understand whether change in neurological symptoms over time can be predicted by
regional brain morphometry. Such information could strengthen the clinical relevance of these measures as outcomes for clinical trials, and lead to a better understanding of the key neuropathological changes in Wolfram
syndrome that deserve further attention.
The major strength of this study is the longitudinal quantification of structural brain abnormalities in
Wolfram syndrome compared to well-matched controls using voxel-wise and regional approaches. However,
there are some limitations to our study. First, although all Wolfram group members who were willing to travel to
St. Louis were accepted into the study, this requirement may have selected for individuals who were less severely
affected than the general Wolfram syndrome population. Second, the maximum number of years that the control
group was followed was shorter (n = 3) than for the Wolfram group (n = 7). Fortunately, mixed model statistical
approaches are designed to handle this difference. In addition our primary results were quite robust and patterns
can be seen clearly at the raw data level. Finally, the scope of this paper included longitudinal volumetric change
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in Wolfram syndrome. Future analyses will need to address longitudinal change in diffusion weighted imaging
and behavior. We ultimately hope to determine whether rates of change in specific symptoms correlates with rate
of change in specific brain regions or tissue types.
Our unique longitudinal neuroimaging dataset in Wolfram syndrome clearly indicate that while some
morphometric brain abnormalities are present very early in the disease course, others appear to increase over
time. The patterns observed suggest that both altered neurodevelopmental and degenerative processes occur in
Wolfram syndrome distributed across region and tissue type. Animal models of Wolfram syndrome are improving57, with recent papers suggesting gross neurologic alterations that resemble the basic cross-sectional differences seen in human neuroimaging. The challenge remains to verify in animal models the longitudinal patterns
seen here in our analyses and to determine whether there is a unifying primary mechanism that can explain both
the spatial and tissue-specific patterns. Furthermore, understanding the predictive value of gene mutation for rate
of progression of neurologic symptoms and brain degeneration is a future goal requiring larger samples. These
issues have been explored in the past using retrospectively acquired basic clinical information (e.g. reported age
of onset of symptoms)6,58. Future work will need to examine genotype-phenotype relationships using objective,
quantified and longitudinal neuroimaging metrics, as presented in this paper, with a larger and more diverse
sample.

Data Availability

The raw data used in the analyses described in this manuscript cannot be made available in the manuscript, supplemental files, or a public repository because the sample size of our Wolfram syndrome patient group is so small,
and the disease so rare, that human participant characteristics such as sex, age, and number of visits could be
used to identify individuals even after de-identification of the data. The corresponding author, Dr. Hershey, may
be contacted to request data. As per the Human Research Protection Office (HRPO) at Washington University, a
preface to data sharing agreement and a data sharing agreement reviewed by the research office will be employed
prior to data sharing. HRPO regulations permit access to potentially identifiable data only to research personnel
on our study protocol and approved through the University.
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